These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15154827)

  • 1. A problem-oriented approach to safety issues in drug development and beyond.
    Haas JF
    Drug Saf; 2004; 27(8):555-67. PubMed ID: 15154827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications.
    Haque A; Daniel S; Maxwell T; Boerstoel M
    Clin Ther; 2017 Apr; 39(4):675-685. PubMed ID: 28392076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Making Patient-focused Information Provision a Reality: One Company's Approach].
    Takemoto S
    Yakugaku Zasshi; 2018; 138(3):315-323. PubMed ID: 29503422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric cardiovascular safety: challenges in drug and device development and clinical application.
    Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW
    Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The art and science of risk management: a US research-based industry perspective.
    Bush JK; Dai WS; Dieck GS; Hostelley LS; Hassall T
    Drug Saf; 2005; 28(1):1-18. PubMed ID: 15649102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The periodic safety update report as a pharmacovigilance tool.
    Klepper MJ
    Drug Saf; 2004; 27(8):569-78. PubMed ID: 15154828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
    Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
    Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodologic challenges to studying patient safety and comparative effectiveness.
    Strom BL
    Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
    Kraft WK; Waldman SA
    Drug Saf; 2001; 24(9):637-43. PubMed ID: 11522118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.